Autor/Autores: Hartmut Goldschmidt; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators

Goldschmidt H et al; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0. PMID: 36328040.

Autor/Autores: Xavier Leleu et al

Leleu X et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med. 2024 Aug;30(8):2235-2241. doi: 10.1038/s41591-024-03050-2. Epub 2024 Jun 3. PMID: 38830994; PMCID: PMC11333283.

Autor/Autores: Thierry Facon, Meletios-Athanasios Dimopoulos, Xavier P Leleu, Meral Beksac, Ludek Pour, Roman Hájek, Zhuogang Liu, Jiri Minarik, Philippe Moreau, Joanna Romejko-Jarosinska, Ivan Spicka, Vladimir I Vorobyev, Britta Besemer, Tadao Ishida, Wojciech Janowski, Sevgi Kalayoglu-Besisik, Gurdeep Parmar, Pawel Robak, Elena Zamagni, Hartmut Goldschmidt, Thomas G Martin, Salomon Manier, Mohamad Mohty, Corina Oprea, Marie-France Brégeault, Sandrine Macé, Christelle Berthou, David Bregman, Zandra Klippel, Robert Z Orlowski; IMROZ Study Group

Facon T et al; IMROZ Study Group. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Jun 3. doi: 10.1056/NEJMoa2400712. Epub ahead of print. PMID: 38832972.

Autor/Autores: Thierry Facon1 | Philippe Moreau2 | Thomas G. Martin3 | Ivan Spicka4 | Albert Oriol5 | Youngil Koh6 | Andrew Lim7 | Gabor Mikala8 | Laura Rosiñol9 | Münci Yağci10 | Michele Cavo11 | Kwee Yong12 | Marie‐Laure Risse13 | Gaëlle Asset14 | Sandrine Schwab14 | Gracia Martinez15

Facon T, Moreau P, Martin TG, Spicka I, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, Cavo M, Yong K, Risse ML, Asset G, Schwab S, Martinez G. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematol Oncol. 2022 Dec;40(5):1020-1029. doi: 10.1002/hon.3038. Epub 2022 Jun 8. PMID: 35653225; PMCID: PMC10084276.

Autor/Autores: Thierry Facon, Philippe Moreau, Ross Baker, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Nicole M. Armstrong, Christina Tekle, Sandrine Schwab, Marie-Laure Risse, and Thomas Martin

Facon T, Moreau P, Baker R, Min CK, Leleu X, Mohty M, Karlin L, Armstrong NM, Tekle C, Schwab S, Risse ML, Martin T. Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis. Haematologica. 2023 Aug 17. doi: 10.3324/haematol.2023.283073. Epub ahead of print. PMID: 37584290.

Autor/Autores: Rodriguez-Merchan, E. Carlos

Rodriguez-Merchan EC. Hemophilic arthropathy: how to diagnose subclinical bleeding early and how to orthopedically treat a damaged joint. Expert Rev Hematol. 2023 Jul-Dec;16(9):651-658. doi: 10.1080/17474086.2023.2232547. Epub 2023 Jul 4. PMID: 37392151.

Autor/Autores: Mancuso, Maria Elisa; Croteau, Stacy E.; Klamroth, Robert

Mancuso ME, Croteau SE, Klamroth R. Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologies. Haemophilia. 2024 Apr;30 Suppl 3:39-44. doi: 10.1111/hae.14976. Epub 2024 Mar 13. PMID: 38481077.

Autor/Autores: Okaygoun, Dide; Oliveira, Danielle D.; Soman, Sooriya; Williams, Riccardo

Okaygoun D, Oliveira DD, Soman S, Williams R. Advances in the management of haemophilia: emerging treatments and their mechanisms. J Biomed Sci. 2021 Sep 14;28(1):64. doi: 10.1186/s12929-021-00760-4. PMID: 34521404; PMCID: PMC8442442.

Autor/Autores: Nogami, Keiji; Shima, Midori

Nogami K, Shima M. Current and future therapies for haemophilia-Beyond factor replacement therapies. Br J Haematol. 2023 Jan;200(1):23-34. doi: 10.1111/bjh.18379. Epub 2022 Jul 23. PMID: 35869698.

Autor/Autores: Saad Z. Usmani 1 , Chatchada Karanes2, William I. Bensinger3, Anita D’Souza 4, Noopur Raje5, Sascha A. Tuchman 6, Douglas Sborov7 ,Jacob P. Laubach 8, Giada Bianchi 8 , Dheepak Kanagavel9 , Rao Saleem10 , Franck Dubin9 ,Frank Campana10,11 ,Paul G. Richardson 8

Usmani SZ, Karanes C, Bensinger WI, D'Souza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, Saleem R, Dubin F, Campana F, Richardson PG. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 2021 Dec;35(12):3526-3533. doi: 10.1038/s41375-021-01262-w. Epub 2021 May 28. PMID: 34050260; PMCID: PMC8632673.

Autor/Autores: Paul G Richardson, Aurore Perrot, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Jeffrey Shang-Yi Huang, Jiri Minarik, Michele Cavo, H Miles Prince, Laure Malinge, Franck Dubin, Helgi van de Velde, Kenneth C Anderson

Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022 Mar;23(3):416-427. doi: 10.1016/S1470-2045(22)00019-5. Epub 2022 Feb 10. Erratum in: Lancet Oncol. 2022 Apr;23(4):e161. Erratum in: Lancet Oncol. 2022 Sep;23(9):e404. PMID: 35151415.

Autor/Autores: Meral Beksac a,*, Ivan Spicka b, Roman Hajek c, Sara Bringhen d, Tomas Jelínek e, Thomas Martin f, Gabor Mikala g, Philippe Moreau h, Argiris Symeonidis i, Andreea M. Rawlings j, Helgi van de Velde j, Paul G. Richardson

Beksac M, Spicka I, Hajek R, Bringhen S, Jelínek T, Martin T, Mikala G, Moreau P, Symeonidis A, Rawlings AM, van de Velde H, Richardson PG. Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA. Leuk Res. 2022 Nov;122:106948. doi: 10.1016/j.leukres.2022.106948. Epub 2022 Sep 6. PMID: 36108425.

Autor/Autores: Philippe Moreau*, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Thomas Martin*, on behalf of the IKEMA study group†

Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. PMID: 34097854.

Autor/Autores: Thomas Martin 1,22, Meletios-Athanasios Dimopoulos 2, Joseph Mikhael 3, Kwee Yong 4, Marcelo Capra5, Thierry Facon6, Roman Hajek 7, Ivan Špička8, Ross Baker9, Kihyun Kim10, Gracia Martinez11, Chang-Ki Min12, Ludek Pour13, Xavier Leleu 14, Albert Oriol 15, Youngil Koh16, Kenshi Suzuki17, France Casca18, Sandrine Macé19, Marie-Laure Risse20 and Philippe Moreau21,22

Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023 Sep 27;13(1):152. doi: 10.1038/s41408-023-00923-6. Erratum for: Blood Cancer J. 2023 May 9;13(1):72. PMID: 37752114; PMCID: PMC10522597.

Autor/Autores: Michel Attal*, Paul G Richardson*, S Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Jeffrey Shang-Yi Huang, Jiri Minarik, Michele Cavo, H Miles Prince, Sandrine Macé, Kathryn P Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C Anderson, on behalf of the ICARIA-MM study group

Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Erratum in: Lancet. 2019 Dec 7;394(10214):2072. PMID: 31735560.

Autor/Autores: Meletios A. Dimopoulos1 Xavier Leleu2 Philippe Moreau3 Paul G. Richardson4 Anna Marina Liberati5 Simon J. Harrison6 H. Miles Prince7 Enrique M. Ocio8 Sylvie Assadourian9 Frank Campana10 Laure Malinge11 Dorothée Sémiond9 Helgi van de Velde10 Kwee Yong12

Dimopoulos MA, Leleu X, Moreau P, Richardson PG, Liberati AM, Harrison SJ, Miles Prince H, Ocio EM, Assadourian S, Campana F, Malinge L, Sémiond D, van de Velde H, Yong K. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia. 2021 Feb;35(2):562-572. doi: 10.1038/s41375-020-0868-z. Epub 2020 May 23. PMID: 32444867; PMCID: PMC7862055.

Autor/Autores: Ivan Spicka1 | Philippe Moreau2 | Thomas G. Martin3 | Thierry Facon4 | Gracia Martinez5 | Albert Oriol6 | Youngil Koh7 | Andrew Lim8 | Gabor Mikala9 | Laura Rosiñol10 | Münci Yagci11 | Michele Cavo12,13 | Marie-Laure Risse14 | Gaëlle Asset15 | Sandrine Macé14 | Helgi van de Velde16 | Kwee Yong17

Spicka I, Moreau P, Martin TG, Facon T, Martinez G, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, Cavo M, Risse ML, Asset G, Macé S, van de Velde H, Yong K. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. Eur J Haematol. 2022 Nov;109(5):504-512. doi: 10.1111/ejh.13835. Epub 2022 Aug 18. PMID: 35871357; PMCID: PMC9804737.

Autor/Autores: Marcelo Capra,1 Thomas Martin,2 Philippe Moreau,3 Ross Baker,4 Ludek Pour,5 Chang-Ki Min,6 Xavier Leleu,7 Mohamad Mohty,8 Marta Reinoso Segura,9 Mehmet Turgut,10 Richard LeBlanc,11 Marie-Laure Risse,12 Laure Malinge,13 Sandrine Schwab12 and Meletios Dimopoulos14

Capra M, Martin T, Moreau P, Baker R, Pour L, Min CK, Leleu X, Mohty M, Segura MR, Turgut M, LeBlanc R, Risse ML, Malinge L, Schwab S, Dimopoulos M. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. Haematologica. 2022 Jun 1;107(6):1397-1409. doi: 10.3324/haematol.2021.279229. PMID: 34647444; PMCID: PMC9152981.

Autor/Autores: Meletios A. Dimopoulos1 , Philippe Moreau2 , Bradley Augustson3, Nelson Castro4, Tomas Pika5, Sosana Delimpasi6 , Javier De la Rubia7, Angelo Maiolino8, Tony Reiman9, Joaquin Martinez-Lopez10, Thomas Martin11, Joseph Mikhael12 , Kwee Yong13, Marie-Laure Risse14, Gaelle Asset15, Sylvia Marion16, Roman Hajek17,18

Dimopoulos MA, Moreau P, Augustson B, Castro N, Pika T, Delimpasi S, De la Rubia J, Maiolino A, Reiman T, Martinez-Lopez J, Martin T, Mikhael J, Yong K, Risse ML, Asset G, Marion S, Hajek R. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. Am J Hematol. 2023 Jan;98(1):E15-E19. doi: 10.1002/ajh.26602. Epub 2022 Jun 4. PMID: 35604280; PMCID: PMC10084376.

Autor/Autores: Xavier Leleu, Thomas Martin, Katja Weisel, Fredrik Schjesvold, Shinsuke Iida, Fabio Malavasi, Salomon Manier, Chang-Ki Min, Enrique M Ocio, Charlotte Pawlyn, Aurore Perrot, Hang Quach, Joshua Richter, Ivan Spicka, Kwee Yong, Paul G Richardson

Leleu, Xavier et al. “Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.” Annals of hematology vol. 101,10 (2022): 2123-2137. doi:10.1007/s00277-022-04917-5